Redx Pharma Plc (LON:REDX)

Redx Pharma Plc (LON:REDX)


Share Price
5.25 p
Change
0 (0.00 %)
Market Cap
£6.64 m
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Deinove return rights to Redx Programme


RNS Number : 5701O
Redx Pharma plc
31 January 2019
 

REDX PHARMA PLC

("Redx" or "the Company")

 

Deinove return rights to Redx's Anti-infective Programme

 

Alderley Park, 31 January 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that Deinove has decided not to exercise their option for Redx's Novel Bacterial Topoisomerase Inhibitor (NBTI) programme. This decision follows a period of nine months of evaluation by Deinove, during which Deinove had sole rights to develop the programme.

 

All rights to the NBTI programme, including all new data generated by Deinove, now revert to Redx, who are exploring options for the programme with other parties with potential interest in licensing the project.

 

Redx entered into an option and license agreement with Deinove for the NBTI programme in March 2018 following a strategic decision to close the Redx anti-infectives unit in 2017, and focus the Company on developing new medicines in Oncology and Fibrosis.  Last week, the Company announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has given formal approval to the Company to re-commence the phase 1/2a trial for RXC004, an oral porcupine inhibitor targeting the Wnt signalling pathway. Clinical evaluation of RXC004 in patients with advanced solid tumours remains on track to resume in H1 2019 following the approval of a revised phase 1/2a clinical trial protocol and drug formulation. 

 

For further information, please contact:

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

 

Andrew Saunders, Chief Medical Officer

 

 

 

Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)

T: +44 20 7894 7000

Phil Davies

 

 

 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

 

 

About Redx Pharma Plc 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCLLFIVLLIIVIA

Redx Pharma Plc Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use